Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries

Clinical Therapeutics

Volumn 30, Issue 8, 2008, Pages 1508-1523

  Ara, Roberta ^a   Pandor, Abdullah ^a   Tumur, Indra ^a   Paisley, Suzy ^a   Duenas, Alejandra ^a   Williams, Robert ^a   Wilkinson, Anna ^a   Durrington, Paul ^b   Chilcott, Jim ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Cardiovascular Research Group   (United Kingdom)

Author keywords

cardiovascular disease; cost; cost effectiveness; ezetimibe; statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE REGISTRY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH STATUS; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTEMATIC REVIEW; UNITED KINGDOM;

AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SEX FACTORS;

EID: 51549104055     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.08.002     Document Type: Article

References (44)

1. World Health Organization. The World Health Report 2002-Reducing Risks, Promoting Healthy Life (2002), World Health Organization, Geneva, Switzerland
2. British Heart Foundation. Reducing your blood cholesterol. Health Information Series No. 3 (2004), British Heart Foundation, London, UK
3. McPherson K., Britton A., and Causer L. CHD: Estimating the Impact of Changes in Risk Factors (2002), National Heart Forum, London, UK
4. Primatesta P., and Poulter N.R. Levels of dyslipidaemia and improvement in its management in England: Results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 64 (2006) 292-298
5. Ward S., Lloyd Jones M., Pandor A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11 (2007) 1-160
6. Committee for Medical Products for Human Use. Note for Guidance on Clinical Investigation of Medical Products in the Treatment of Lipid Disorders (2004-July 21, 2008), European Medicines Agency, London, UK. http://emea.europa.eu/pdfs/human/ewp/302003en.pdf Accessed
7. Health Care Statistics. Prescription cost analysis, England 2003 (2003-October 9, 2006), Department of Health, London, UK. www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4086603 Accessed
8. National Health Services Health and Social Care Information Centre. Health care statistics. Prescription cost analysis, 2005 (October 9, 2006). http://www.ic.nhs.uk/pubs/prescostanalysis2005 Accessed
9. Welsh Assembly Government. Prescriptions dispensed in the community in Wales, 2000 to 2005 and prescription cost analysis (PCA) data (October 9, 2006). http://new.wales.gov.uk/topics/statistics/headlines/health-2007/health-2006/hdw20060518/?lang=en Accessed
10. Ara R., Tumur I., Pandor A., et al. Ezetimibe for the treatment of hypercholesterolaemia: A systematic review and economic evaluation. Health Technol Assess 12 (2008) 1-232
11. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [published correction appears in Lancet. 2005;366:1358]. Lancet 366 (2005) 1267-1278
12. Curtis L., and Netten A. Unit costs of health and social care 2006 (July 3, 2006). http://www.pssru.ac.uk/uc/uc2006contents.htm Accessed
13. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: A practical guide. Med Decis Making 13 (1993) 322-338
14. National Institute for Clinical Excellence (NICE). Guide to the methods of Technology Appraisal (reference NO515) (September 7, 2006). http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf Accessed
15. British Heart Foundation statistics database. BHF 2004 (September 10, 2007). http://www.heartstats.org/atozpage.asp?id=2478 Accessed
16. Gray D., and Hampton J.R. Twenty years' experience of myocardial infarction: The value of a heart attack register. Br J Clin Pract 47 (1993) 292-295
17. Wolfe C.D., Rudd A.G., Howard R., et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: The South London Stroke Register. J Neurol Neurosurg Psychiatry 72 (2002) 211-216
18. Bays H.E., Ose L., Fraser N., et al., Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
19. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
20. Goldberg A.C., Sapre A., Liu J., et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, doubleblind, placebo-controlled trial. Mayo Clin Proc 79 (2004) 620-629
21. Rodney R.A., Sugimoto D., Wagman B., et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc 98 (2006) 772-778
22. Ballantyne C.M., Houri J., Notarbartolo A., et al., Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
23. Melani L., Mills R., Hassman D., et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 24 (2003) 717-728
24. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
25. Joint Formulary Committee British National Formulary. 52nd ed. (2006), British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK www.bnf.org. Accessed October 9, 2006
26. Palmer S., Sculpher M., Philips Z., et al. A Cost-Effectiveness Model Comparing Alternative Management Strategies for the Use of Glycoprotein IIb/IIIa Antagonists in Non-ST-Elevation Acute Coronary Syndrome (2002), National Institute for Clinical Excellence, London, UK
27. Clarke P., Gray A., Legood R., et al. The impact of diabetes-related complications on healthcare costs: Results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 20 (2003) 442-450
28. Youman P., Wilson K., Harraf F., and Kalra L. The economic burden of stroke in the United Kingdom. Pharmaco-Economics 21 Suppl 1 (2003) 43-50
29. Lenzen M., Scholte op Reimer W., Norekvål T.M., et al. Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Results from the Euro Heart Survey on Coronary Revascularization. Eur J Cardiovasc Nurs 5 (2006) 115-121
30. BARI Investigators. Protocol for the bypass angioplasty revascularization investigation. Circulation 84 Suppl 6 (1991) V1-V27
31. Kim J., Henderson R.A., Pocock S.J., et al., RITA-3 Trial Investigators. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol 45 (2005) 221-228
32. Goodacre S., Nicholl J., Dixon S., et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 328 (2004) 254
33. van Exel N.J., Scholte op Reimer W.J., and Koopmanschap M.A. Assessment of post-stroke quality of life in cost-effectiveness studies: The usefulness of the Barthel Index and the Euro-Qol-5D. Qual Life Res 13 (2004) 427-433
34. Leeds L., Meara J., and Hobson P. The impact of discharge to a care home on longer term stroke outcomes. Clin Rehabil 18 (2004) 924-928
35. Pickard A.S., Johnson J.A., and Feeny D.H. Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res 14 (2005) 207-219
36. Kind P., Dolan P., Gudex C., and Williams A. Variations in population health status: Results from a United Kingdom national questionnaire survey. BMJ 316 (1998) 736-741
37. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmaco-Economics 17 (2000) 479-500
38. In: Drummond M.F., Sculpher M.J., Torrance G.W., et al. (Eds). Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. (2005), Oxford University Press, Oxford, UK
39. Law A.M. Simulation Modeling & Analysis. 4th ed (2006), McGraw-Hill, New York, NY
40. Cook J.R., Yin D., Alemao E., et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: Application to Germany, Spain and Norway. PharmacoEconomics 22 Suppl 3 (2004) 49-61
41. Organisation for Economic Cooperation and Development Purchasing Power Parities (July 3, 2006). http://www.oecd.org/department/ Accessed
42. Kohli M., Attard C., Lam A., et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. PharmacoEconomics 24 (2006) 815-830
43. Anderson K.M., Wilson P.W., Odell P.M., and Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
44. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443